1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. JUBILANT PHARMOVA LTD.
Jubilant Pharmova Ltd.
NSE: JUBLPHARMA | BSE: 530019

Jubilant Pharmova Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 2 Starfolio Baskets
aboutJubilant Pharmova Limited is an integrated global pharmaceutical company with a significant presence in radiopharmaceuticals, allergy immunotherapy, and contract manufacturing. The company operates across the pharmaceutical value chain, from drug dis... Read More
ANDA Approvals
Ask AI about Jubilant Pharmova
923.80-22.20(-2.35%)
59,809
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
44.8 / 100
Mid-range PerformerThese stocks have average quality, financial and technical momentum, indicating a mid range performerView SimilarEmbed DVM
Analyst Price Target
-

5

S

10

W

6

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

12Positive11Negative

Pass in checklist52.2%

045
55
100

PE Valuation Check

Right Now
Undervalued
38.4%
1 Year Forward
Undervalued
75.9%
INSIGHTJubilant Pharmova is undervalued at both current PE and future earnings estimates.

Jubilant Pharmova Stock Price Analysis

Day Price Range

-2.4% 1 Day return
923.8 (LTP)
920951.8
LowHigh

Week Price Range

-1.6% 1 Week return
923.8 (LTP)
918965.9
LowHigh

Month Price Range

-10.2% 1 Month return
923.8 (LTP)
895.11,028.6
LowHigh

52 Week Price Range

-16.1% 1 Year return
923.8 (LTP)
7861,183
LowHigh
View full Price History/Seasonality

Jubilant Pharmova Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Jubilant Pharmova's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

CURRENT EPS
24.1
AVG. ESTIMATE
24.1
LOW ESTIMATE
24.1
HIGH ESTIMATE
24.1
CURRENT EPS
AVG. ESTIMATE

Consensus Recommendation

2 ANALYST Recommendations
HOLD

The consensus recommendation from 2 analysts for Jubilant Pharmova is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Jubilant Pharmova Technical Analysis

Jubilant Pharmova EMA & SMA

Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
5 Day937.8
10 Day941.8
12 Day944.0
20 Day952.6
26 Day956.7
50 Day961.5
100 Day961.5
200 Day969.3

Jubilant Pharmova Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202637.1%
Week43.0%
Month60.9%

Jubilant Pharmova Active Candlesticks

Hikkake Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Jubilant Pharmova Resistance and Support

931.87
Pivot
First Resistance943.7
Second Resistance963.7
Third Resistance975.5
First Support911.9
Second Support900.1
Third Support880.1
Day RSI38.8
Day MACD-12.8
Day MFI54
Day MACD Signal Line-11.8

Jubilant Pharmova Beta

1 Month0.5
1 Year0.6
3 Month0.2
3 Year0.8

Jubilant Pharmova Price Change Analysis

↓-10.2%
Over 1 Month
LowHigh
895.11028.6
↓-1.2%
Over 3 Months
LowHigh
847.91091.9
↓-0.3%
Over 6 Months
LowHigh
847.91091.9
↓-16.1%
Over 1 Year
LowHigh
786.11183
All Technicals →

Jubilant Pharmova Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Spb Trustee Company Pvt LtdPromoter31,986,16120.1 %
Government Pension Fund GlobalFii4,481,4602.8 %
Rekha JhunjhunwalaPublic10,244,0006.4 %
Bandhan Small Cap FundDii6,387,7234.0 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Jubilant Pharmova Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
QUANT MUTUAL FUNDBlockSell12 Oct 20269151,100,000NSE
ABAKKUS FOUR2EIGHT OPPORTUNITIES FUNDBlockPurchase12 Oct 20269151,100,000NSE
QUANT MUTUAL FUNDBulkSell12 Oct 20269151,100,000NSE
ABAKKUS FOUR2EIGHT OPPORTUNITIES FUNDBulkPurchase12 Oct 20269151,100,000NSE
QUANT MUTUAL FUNDBulkSell12 Oct 2026915.01981,704BSE
NIKITA RESOURCES PRIVATE LIMITEDBulkSell13 Jun 20251060.371,962,434NSE
JUBILANT ENPRO PRIVATE LIMITEDBulkSell13 Jun 202510602,116,000NSE
KOTAK MAHINDRA MUTUAL FUNDBulkPurchase13 Jun 202510601,693,434NSE
KOTAK FUNDS - INDIA MIDCAP FUNDBulkPurchase13 Jun 202510601,593,500NSE
EAST BRIDGE CAPITAL MASTER FUND LIMITEDBlockSell18 Mar 2025856.25623,585NSE
All deals
All insider trades

Jubilant Pharmova Corporate Actions

Jubilant Pharmova Dividend history and yield

Jubilant Pharmova dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Jubilant Pharmova dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
5FINAL24 Jul 2026Equity Share
225 Jul 2025
5FINAL25 Jul 2025Equity Share
302 Aug 2024
5FINAL02 Aug 2024Equity Share
410 Aug 2023
5FINAL10 Aug 2023Equity Share
511 Aug 2022
5FINAL12 Aug 2022Equity Share

Jubilant Pharmova Bonus shares

Jubilant Pharmova bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
112 Mar 2004
3:515 Mar 2004

Jubilant Pharmova Board Meetings

Jubilant Pharmova past and upcoming board meetings.

#Ex-Date
PurposeNotes
113 Nov 2026
Quarterly Results-
212 Oct 2026
To approve raising of funds-
310 Aug 2026
Quarterly Results(Revised)
422 May 2026
Audited Results & Final Dividend-
506 Feb 2026
Quarterly Results-

Jubilant Pharmova Stock Split

Jubilant Pharmova stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
117 Mar 2006
5124 Mar 2006
212 Nov 2002
10521 Nov 2002
All Corporate Actions

Jubilant Pharmova Research Reports

Jubilant Pharmova research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
107 Feb 2026ICICI Direct1310937.65Buy39.71%-1.48%pdf
214 Jan 2026Ventura15571066.3Buy46.02%-13.36%pdf
304 Nov 2025ICICI Direct
Reco
Target
14151181.2Buy19.79%-21.79%pdf
428 Oct 2022ICICI Direct
Reco
Target
395371.5Hold6.33%148.67%pdf
524 Oct 2022ICICI Securities Limited
Reco
Target
417335.9Buy24.14%175.02%pdf
All Reports of Jubilant

Jubilant Pharmova Corporate Filings

Jubilant Pharmova BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Unaudited standalone and consolidated financial results of the company for the quarter and half year ended September 30, 2026
PDF
23 Oct 2026
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication
PDF
22 Oct 2026
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication
PDF
21 Oct 2026
Jubilant Pharmova Ltd - 530019 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice
PDF
21 Oct 2026
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating
PDF
VIEW ALL

Jubilant Pharmova DocumentsAsk MarketMind AI

Jubilant Pharmova Earnings Call

Jubilant Pharmova earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
27 May 2026Jubilant Pharmova Ltd - 530019 - Earnings Call TranscriptLink
24 Feb 2025Jubilant Pharmova Ltd - 530019 - Audio Recording Of Investors / Analysts MeetingLink
09 Feb 2023Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
03 Feb 2023Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
31 Oct 2022Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
view all

Jubilant Pharmova Annual Reports

Jubilant Pharmova financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link

Jubilant Pharmova Credit Ratings

Jubilant Pharmova credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
20 Oct 2026india ratingsIndia Ratings Assigns Jubilant Pharmova’s Proposed NCDs ‘IND AA+’; Outlook StableLink
13 Oct 2026icra ratingsJubilant Pharmova Limited[ICRA]AA+ (Stable) assignedLink
23 Feb 2026india ratingsIndia Ratings Withdraws Jubilant Pharmova’s Debt RatingsLink
04 May 2025india ratingsIndia Ratings Assigns Jubilant Pharmova’s CP ‘IND A1+’; Affirms Bank Facilities at ‘IND AA+’/StableLink
08 Dec 2024india ratingsIndia Ratings Revises Outlook on Jubilant Pharmova’s Bank Facilities to Stable; Affirms ‘IND AA+’Link

Jubilant Pharmova Investor Presentations

Jubilant Pharmova investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
18 Jun 2021Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
03 Feb 2015Announces Q3 Results, Results Press Release, Investors Presentation & Limited Review Report for Dec 31, 2014Link

Jubilant Pharmova - Company Profile

Jubilant Pharmova Management Structure

Jubilant Pharmova management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Naresh KapoorCompany Secretary-Mar 26
Mr. Arun Kumar SharmaChief Financial Officer-Mar 26

Jubilant Pharmova Board of Directors

Jubilant Pharmova Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Priyavrat BhartiaED / MD / Promoter749.6Mar 26
Arjun Shanker BhartiaED / Joint MD / Promoter749.6Mar 26
S K RoongtaIndependent Non Exe. Director34.75Mar 26
Arun Seth.Independent Non Exe. Director33.75Mar 26
Vivek MehraIndependent Non Exe. Director32.5Mar 26
Shivpriya NandaIndependent Non Exe. Director31.75Mar 26
Harsh MahajanIndependent Non Exe. Director26.5Mar 26
Shirish Gundopant BelapureIndependent Non Exe. Director25.75Mar 26
Shyam S BhartiaChairman & Non Executive Dir.24Mar 26
Hari S BhartiaCo-Chairman / Non Executive Director / Promoter21Mar 26
Naresh KapoorCompany Secretary / Compliance Officer-Mar 26
Website: www.jubl.com

About the company - Business Profile

Jubilant Pharmova Limited is an integrated global pharmaceutical company with a significant presence in radiopharmaceuticals, allergy immunotherapy, and contract manufacturing. The company operates across the pharmaceutical value chain, from drug discovery and development to the commercialization of generics and proprietary novel drugs. It holds a leading position in the North American radiopharmaceutical market and maintains a diversified business model aimed at high-growth, innovation-led segments.

Key Points

  • Key Facts: Founded in 1978 and headquartered in Noida, Uttar Pradesh, India, the company is listed on the BSE and NSE. It was formerly known as Jubilant Life Sciences Limited before its demerger of the Life Science Ingredients business in 2021.
  • Operations and Resources: The company operates several manufacturing facilities across India (Bengaluru, Noida, Roorkee, and Mysore) and North America (Montreal, Canada; Spokane and Salisbury, USA). Its radiopharmaceutical segment includes a network of radiopharmacies in the United States.
  • Market Significance: It is a major supplier in the North American radiopharmaceuticals and allergy immunotherapy markets. The company serves global pharmaceutical and biotech firms through its CDMO (Contract Development and Manufacturing Organisation) and CRDMO (Contract Research, Development and Manufacturing Organisation) arms.
  • Revenue Breakdown (FY2025):
    • Radiopharma: ₹33,880 million (46.8% of total revenue)
    • CDMO Sterile Injectables: ₹12,717 million (17.6%)
    • CRDMO: ₹11,510 million (15.9%)
    • Allergy Immunotherapy: ₹7,013 million (9.7%)
    • Generics: ₹6,853 million (9.5%)
    • Geographical Revenue: Americas and Europe contributed ₹65,937 million (91.1%), India ₹2,127 million (2.9%), and the Rest of the World ₹4,281 million (5.9%).
  • Business Model and Strengths: The company focuses on niche segments with high entry barriers, such as radiopharmaceuticals and sterile injectables. It is proficient in managing complex manufacturing processes and regulatory requirements in global markets.
  • Strategic Initiatives: Under its Vision 2030, the company aims to double its revenue to ₹135,000 million and achieve a 25% EBITDA margin. Key drivers include expanding its PET radiopharmacy network in the US, doubling capacity at the Spokane facility, and launching new SPECT and therapeutic products like MIBG.
  • Recent Developments: In FY2026, the company recorded a gain of ₹217 million from the sale of assets at its Salisbury facility. However, it incurred ₹443 million in expenses due to a temporary manufacturing suspension for remediation at its Montreal facility following "Official Action Indicated" (OAI) observations.
  • Employee Base: The company employs approximately 5,500 multicultural professionals globally.

References

  1. Annual Report May 2025
  2. Result Feb 2026
  3. Result Oct 2025
  4. Annual Report May 2024

Jubilant Pharmova FAQ

Jubilant Pharmova today is trading in the red, down by 2.35% at ₹923.8.
Jubilant Pharmova is currently trading down 2.35% on an intraday basis. In the past week the stock fell 1.55%. Stock has been down 1.21% in the past quarter and fell 16.09% in the past year. You can view this in the share price history/seasonality section.
Jubilant Pharmova is listed on NSE with the ticker JUBLPHARMA and on BSE as 530019. It's currently trading on NSE at a share price of ₹923.8 and on BSE with a share price of ₹926.8.
The market cap of Jubilant Pharmova is ₹14,714.39 Cr. as of Oct 30, 2026.
Jubilant Pharmova announced a FINAL dividend of 500% which equals ₹5 in Jul 24, 2026.The last three ex-dates for Jubilant Pharmova were Jul 25, 2025, Aug 02, 2024 and Aug 10, 2023. To view the full dividend history of Jubilant Pharmova click here.
Jubilant Pharmova has undergone 2 stock splits and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Jubilant Pharmova stock split was on Mar 17, 2006 at a ratio of 5:1 and the last bonus share announcement was on Mar 12, 2004 at a ratio of 3:5.
Jubilant Pharmova reported ₹2,249.3 Cr. in revenue, ₹56.5 Cr. in net profit, and ₹267.9 Cr. in EBITD as of Aug 10, 2026 for Q1 FY26-27.
According to the predictions of 2 analysts, the share price prediction for Jubilant Pharmova is ₹1,088.5 with an upside of 18%.
The PE ratio of Jubilant Pharmova is 41.79 as of Oct 30, 2026.
The PB ratio of Jubilant Pharmova is 2.06 as of Oct 30, 2026.
You can view the latest analyst reports on the Jubilant Pharmova reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×